| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 104 | 2024 | 331 | 23.420 |
Why?
|
| Hypertension, Pulmonary | 147 | 2023 | 1737 | 15.800 |
Why?
|
| Nitric Oxide | 112 | 2023 | 827 | 12.220 |
Why?
|
| Lung | 124 | 2024 | 3593 | 9.940 |
Why?
|
| Persistent Fetal Circulation Syndrome | 48 | 2023 | 132 | 9.860 |
Why?
|
| Infant, Premature | 73 | 2024 | 478 | 8.640 |
Why?
|
| Pulmonary Circulation | 75 | 2022 | 408 | 7.580 |
Why?
|
| Pulmonary Artery | 73 | 2021 | 1028 | 6.250 |
Why?
|
| Pulmonary Alveoli | 29 | 2023 | 374 | 5.770 |
Why?
|
| Infant, Newborn | 192 | 2024 | 5035 | 5.680 |
Why?
|
| Animals, Newborn | 53 | 2024 | 777 | 4.450 |
Why?
|
| Fetus | 56 | 2019 | 701 | 4.390 |
Why?
|
| Sheep | 90 | 2018 | 764 | 3.970 |
Why?
|
| Vascular Resistance | 49 | 2021 | 338 | 3.890 |
Why?
|
| Pediatrics | 19 | 2021 | 984 | 3.590 |
Why?
|
| Vascular Endothelial Growth Factor A | 24 | 2023 | 499 | 3.390 |
Why?
|
| Vasodilator Agents | 21 | 2022 | 305 | 3.300 |
Why?
|
| Administration, Inhalation | 76 | 2023 | 642 | 3.170 |
Why?
|
| Nitric Oxide Synthase | 31 | 2007 | 209 | 3.000 |
Why?
|
| Respiration, Artificial | 33 | 2023 | 526 | 2.820 |
Why?
|
| Respiratory Insufficiency | 19 | 2023 | 291 | 2.800 |
Why?
|
| Infant, Premature, Diseases | 11 | 2023 | 89 | 2.800 |
Why?
|
| Vasodilation | 33 | 2011 | 416 | 2.760 |
Why?
|
| Neovascularization, Physiologic | 15 | 2015 | 173 | 2.690 |
Why?
|
| Racism | 5 | 2022 | 102 | 2.680 |
Why?
|
| Hyperoxia | 10 | 2020 | 100 | 2.570 |
Why?
|
| Endothelial Cells | 19 | 2018 | 685 | 2.430 |
Why?
|
| Hypoxia | 33 | 2021 | 960 | 2.380 |
Why?
|
| Lung Diseases | 17 | 2019 | 703 | 2.380 |
Why?
|
| Hemodynamics | 51 | 2022 | 1014 | 2.310 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 15 | 2021 | 102 | 2.300 |
Why?
|
| Humans | 307 | 2024 | 114937 | 2.270 |
Why?
|
| Pregnancy | 78 | 2024 | 5527 | 2.200 |
Why?
|
| rho-Associated Kinases | 7 | 2016 | 80 | 2.110 |
Why?
|
| Endothelium, Vascular | 21 | 2018 | 848 | 2.100 |
Why?
|
| Social Justice | 3 | 2020 | 67 | 2.070 |
Why?
|
| Vascular Diseases | 8 | 2023 | 230 | 2.060 |
Why?
|
| Premature Birth | 10 | 2023 | 276 | 1.970 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 15 | 2022 | 186 | 1.960 |
Why?
|
| Infant | 85 | 2023 | 7937 | 1.940 |
Why?
|
| Endothelin-1 | 17 | 2016 | 167 | 1.930 |
Why?
|
| Gestational Age | 38 | 2024 | 759 | 1.920 |
Why?
|
| Infant, Extremely Premature | 8 | 2023 | 57 | 1.890 |
Why?
|
| Animals | 152 | 2024 | 31839 | 1.880 |
Why?
|
| Endotoxins | 8 | 2024 | 204 | 1.790 |
Why?
|
| Oxygen Inhalation Therapy | 15 | 2019 | 129 | 1.780 |
Why?
|
| Rats | 40 | 2024 | 4963 | 1.720 |
Why?
|
| Female | 175 | 2024 | 59581 | 1.620 |
Why?
|
| Rats, Sprague-Dawley | 29 | 2024 | 2211 | 1.540 |
Why?
|
| Sulfones | 7 | 2013 | 97 | 1.520 |
Why?
|
| Nitric Oxide Synthase Type III | 24 | 2016 | 184 | 1.480 |
Why?
|
| Ductus Arteriosus | 18 | 2012 | 67 | 1.480 |
Why?
|
| Phosphodiesterase Inhibitors | 9 | 2019 | 82 | 1.480 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 9 | 2020 | 103 | 1.390 |
Why?
|
| Piperazines | 7 | 2013 | 313 | 1.390 |
Why?
|
| Societies, Medical | 5 | 2020 | 677 | 1.390 |
Why?
|
| Fetal Blood | 6 | 2017 | 270 | 1.370 |
Why?
|
| Oxygen | 30 | 2021 | 853 | 1.350 |
Why?
|
| Guanylate Cyclase | 6 | 2022 | 32 | 1.340 |
Why?
|
| Endothelins | 13 | 2009 | 61 | 1.320 |
Why?
|
| Mentors | 3 | 2021 | 158 | 1.300 |
Why?
|
| Child Health | 2 | 2020 | 126 | 1.290 |
Why?
|
| Vitamin D | 5 | 2020 | 341 | 1.280 |
Why?
|
| Child | 68 | 2023 | 18366 | 1.280 |
Why?
|
| Social Determinants of Health | 2 | 2020 | 135 | 1.230 |
Why?
|
| Health Status Disparities | 2 | 2020 | 201 | 1.230 |
Why?
|
| Lung Injury | 4 | 2020 | 198 | 1.210 |
Why?
|
| High-Frequency Ventilation | 13 | 2000 | 41 | 1.180 |
Why?
|
| Cardiac Catheterization | 17 | 2022 | 535 | 1.170 |
Why?
|
| Cyclic GMP | 10 | 2011 | 78 | 1.170 |
Why?
|
| Fetal Diseases | 10 | 2007 | 147 | 1.160 |
Why?
|
| Chorioamnionitis | 4 | 2022 | 36 | 1.150 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 6 | 2017 | 93 | 1.150 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 5 | 2022 | 66 | 1.120 |
Why?
|
| Receptors, Endothelin | 9 | 2016 | 49 | 1.120 |
Why?
|
| Down Syndrome | 5 | 2022 | 338 | 1.090 |
Why?
|
| Bronchodilator Agents | 11 | 2019 | 243 | 1.080 |
Why?
|
| Pulmonary Medicine | 5 | 2021 | 87 | 1.080 |
Why?
|
| Disease Models, Animal | 25 | 2021 | 3549 | 1.070 |
Why?
|
| Echocardiography, Doppler | 4 | 2018 | 93 | 1.060 |
Why?
|
| Pulmonary Veins | 6 | 2014 | 85 | 1.050 |
Why?
|
| Infant, Very Low Birth Weight | 7 | 2019 | 66 | 1.020 |
Why?
|
| Hernia, Diaphragmatic | 10 | 2014 | 66 | 1.010 |
Why?
|
| Vasoconstriction | 9 | 2008 | 186 | 1.000 |
Why?
|
| Male | 108 | 2024 | 55663 | 0.980 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 480 | 0.980 |
Why?
|
| Endothelin Receptor Antagonists | 7 | 2013 | 58 | 0.980 |
Why?
|
| Respiratory Tract Diseases | 3 | 2019 | 140 | 0.930 |
Why?
|
| Stem Cells | 5 | 2013 | 546 | 0.930 |
Why?
|
| Respiratory Physiological Phenomena | 2 | 2023 | 29 | 0.930 |
Why?
|
| Hypertrophy, Right Ventricular | 15 | 2016 | 141 | 0.930 |
Why?
|
| Dipyridamole | 7 | 1998 | 26 | 0.920 |
Why?
|
| Signal Transduction | 22 | 2021 | 4525 | 0.910 |
Why?
|
| Surface Plasmon Resonance | 2 | 2021 | 83 | 0.900 |
Why?
|
| Infant, Low Birth Weight | 4 | 2020 | 125 | 0.890 |
Why?
|
| Immunohistochemistry | 15 | 2020 | 1635 | 0.880 |
Why?
|
| Sildenafil Citrate | 9 | 2021 | 57 | 0.870 |
Why?
|
| Physicians | 3 | 2018 | 772 | 0.860 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2023 | 286 | 0.860 |
Why?
|
| Muscle, Smooth, Vascular | 10 | 2009 | 417 | 0.840 |
Why?
|
| Heart Ventricles | 5 | 2021 | 711 | 0.810 |
Why?
|
| Career Choice | 3 | 2014 | 181 | 0.810 |
Why?
|
| Cystic Fibrosis | 15 | 2021 | 956 | 0.800 |
Why?
|
| Pulmonary Gas Exchange | 10 | 2022 | 117 | 0.800 |
Why?
|
| Child Welfare | 2 | 2014 | 192 | 0.790 |
Why?
|
| Vitamin D Deficiency | 3 | 2020 | 158 | 0.790 |
Why?
|
| Precision Medicine | 2 | 2023 | 339 | 0.780 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2013 | 98 | 0.780 |
Why?
|
| Lung Compliance | 2 | 2020 | 49 | 0.770 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2022 | 360 | 0.770 |
Why?
|
| Bronchial Arteries | 2 | 2018 | 11 | 0.760 |
Why?
|
| Disease Management | 4 | 2019 | 563 | 0.750 |
Why?
|
| Child, Preschool | 41 | 2021 | 9086 | 0.740 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2022 | 109 | 0.740 |
Why?
|
| Chronic Disease | 22 | 2019 | 1593 | 0.740 |
Why?
|
| Peptide PHI | 1 | 2020 | 4 | 0.730 |
Why?
|
| Early Diagnosis | 3 | 2021 | 217 | 0.730 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 83 | 0.720 |
Why?
|
| Glycogen Storage Disease | 1 | 2020 | 20 | 0.720 |
Why?
|
| Echocardiography | 13 | 2019 | 555 | 0.720 |
Why?
|
| Neovascularization, Pathologic | 4 | 2015 | 283 | 0.710 |
Why?
|
| Benzoates | 2 | 2011 | 38 | 0.710 |
Why?
|
| Nitroarginine | 17 | 2007 | 48 | 0.710 |
Why?
|
| Pregnancy, Animal | 1 | 2020 | 52 | 0.710 |
Why?
|
| Serotonin | 2 | 2013 | 296 | 0.710 |
Why?
|
| Bleomycin | 4 | 2016 | 228 | 0.700 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2020 | 68 | 0.700 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 3 | 2021 | 18 | 0.700 |
Why?
|
| Birth Weight | 5 | 2020 | 440 | 0.700 |
Why?
|
| Indoles | 9 | 2020 | 306 | 0.700 |
Why?
|
| Trachea | 5 | 2017 | 235 | 0.690 |
Why?
|
| Vascular Stiffness | 5 | 2019 | 408 | 0.690 |
Why?
|
| Angiogenic Proteins | 1 | 2020 | 18 | 0.690 |
Why?
|
| Pyrroles | 9 | 2020 | 183 | 0.690 |
Why?
|
| Enzyme Activation | 4 | 2012 | 790 | 0.690 |
Why?
|
| Familial Primary Pulmonary Hypertension | 8 | 2023 | 190 | 0.680 |
Why?
|
| Postnatal Care | 1 | 2020 | 66 | 0.680 |
Why?
|
| Health Equity | 1 | 2020 | 53 | 0.670 |
Why?
|
| Heart Defects, Congenital | 14 | 2022 | 665 | 0.670 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2019 | 18 | 0.670 |
Why?
|
| Cells, Cultured | 17 | 2016 | 3897 | 0.670 |
Why?
|
| Biomedical Research | 5 | 2014 | 585 | 0.650 |
Why?
|
| Pyridines | 6 | 2012 | 425 | 0.650 |
Why?
|
| United States | 22 | 2022 | 12211 | 0.650 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2016 | 33 | 0.650 |
Why?
|
| Emphysema | 1 | 2020 | 110 | 0.640 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2011 | 193 | 0.630 |
Why?
|
| Antihypertensive Agents | 8 | 2019 | 429 | 0.630 |
Why?
|
| Blood Pressure | 27 | 2019 | 1537 | 0.630 |
Why?
|
| Arteriovenous Anastomosis | 3 | 2022 | 13 | 0.630 |
Why?
|
| Acetylcholine | 11 | 2009 | 178 | 0.630 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 523 | 0.620 |
Why?
|
| Science | 2 | 2016 | 48 | 0.620 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 4 | 2016 | 27 | 0.620 |
Why?
|
| Vitamins | 6 | 2019 | 151 | 0.620 |
Why?
|
| Enzyme Inhibitors | 15 | 2009 | 752 | 0.610 |
Why?
|
| Protein Precursors | 6 | 2000 | 119 | 0.610 |
Why?
|
| Superoxide Dismutase | 5 | 2015 | 305 | 0.610 |
Why?
|
| Blotting, Western | 11 | 2020 | 1151 | 0.610 |
Why?
|
| Fetal Growth Retardation | 6 | 2022 | 467 | 0.590 |
Why?
|
| Bone Marrow Cells | 3 | 2009 | 267 | 0.590 |
Why?
|
| Pulmonary Emphysema | 2 | 2020 | 280 | 0.590 |
Why?
|
| Longevity | 1 | 2018 | 137 | 0.590 |
Why?
|
| Cardiology | 1 | 2020 | 259 | 0.580 |
Why?
|
| Pulmonary Surfactants | 5 | 2023 | 101 | 0.580 |
Why?
|
| Epoprostenol | 5 | 2021 | 133 | 0.570 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 8 | 2015 | 86 | 0.560 |
Why?
|
| Hospitalization | 4 | 2015 | 1754 | 0.560 |
Why?
|
| Exosomes | 1 | 2018 | 91 | 0.550 |
Why?
|
| Prospective Studies | 18 | 2023 | 6218 | 0.550 |
Why?
|
| Collagen Type VIII | 1 | 2016 | 2 | 0.550 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2016 | 7 | 0.550 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2017 | 517 | 0.540 |
Why?
|
| Infant Care | 1 | 2016 | 42 | 0.540 |
Why?
|
| Respiration Disorders | 4 | 2019 | 69 | 0.540 |
Why?
|
| Collagen Type IV | 1 | 2016 | 22 | 0.540 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 244 | 0.540 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 162 | 0.540 |
Why?
|
| Pre-Eclampsia | 3 | 2022 | 165 | 0.540 |
Why?
|
| Pulmonary Wedge Pressure | 7 | 2022 | 63 | 0.540 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2016 | 54 | 0.540 |
Why?
|
| Academies and Institutes | 1 | 2016 | 44 | 0.530 |
Why?
|
| Placenta | 5 | 2022 | 626 | 0.530 |
Why?
|
| Altitude | 3 | 2022 | 433 | 0.530 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2016 | 799 | 0.520 |
Why?
|
| Bronchi | 5 | 2021 | 243 | 0.520 |
Why?
|
| Organ Size | 10 | 2009 | 435 | 0.520 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2017 | 452 | 0.520 |
Why?
|
| Faculty, Medical | 1 | 2018 | 232 | 0.520 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2018 | 200 | 0.520 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 6 | 2006 | 17 | 0.510 |
Why?
|
| Congresses as Topic | 2 | 2014 | 198 | 0.510 |
Why?
|
| PPAR gamma | 2 | 2013 | 183 | 0.510 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2015 | 16 | 0.510 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 415 | 0.510 |
Why?
|
| Primary Prevention | 2 | 2014 | 171 | 0.510 |
Why?
|
| Forced Expiratory Volume | 1 | 2017 | 476 | 0.510 |
Why?
|
| Risk | 8 | 2021 | 815 | 0.500 |
Why?
|
| Receptors, Calcitriol | 1 | 2015 | 53 | 0.500 |
Why?
|
| Pulmonary Edema | 4 | 2008 | 116 | 0.500 |
Why?
|
| Endpoint Determination | 1 | 2015 | 69 | 0.490 |
Why?
|
| Cooperative Behavior | 2 | 2022 | 383 | 0.490 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2020 | 515 | 0.490 |
Why?
|
| Capillaries | 2 | 2015 | 91 | 0.490 |
Why?
|
| Cardiovascular Agents | 3 | 2015 | 125 | 0.490 |
Why?
|
| Vascular Endothelial Growth Factors | 5 | 2022 | 61 | 0.490 |
Why?
|
| Magnetic Resonance Imaging, Cine | 4 | 2021 | 174 | 0.480 |
Why?
|
| Early Medical Intervention | 2 | 2014 | 51 | 0.480 |
Why?
|
| Extracorporeal Membrane Oxygenation | 13 | 2015 | 240 | 0.470 |
Why?
|
| Internship and Residency | 2 | 2014 | 944 | 0.470 |
Why?
|
| Phenotype | 10 | 2023 | 2817 | 0.470 |
Why?
|
| Adventitia | 1 | 2014 | 37 | 0.470 |
Why?
|
| Mentoring | 1 | 2016 | 101 | 0.470 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2017 | 104 | 0.460 |
Why?
|
| Smoking | 3 | 2018 | 1391 | 0.460 |
Why?
|
| Treatment Outcome | 25 | 2020 | 9105 | 0.460 |
Why?
|
| Risk Factors | 18 | 2023 | 8637 | 0.460 |
Why?
|
| Pyrazoles | 3 | 2006 | 364 | 0.460 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2019 | 38 | 0.460 |
Why?
|
| Time Factors | 21 | 2021 | 6125 | 0.450 |
Why?
|
| Body Weight | 12 | 2009 | 868 | 0.450 |
Why?
|
| Hyaline Membrane Disease | 4 | 1998 | 20 | 0.450 |
Why?
|
| Radiology | 1 | 2017 | 193 | 0.450 |
Why?
|
| Patient Care Team | 4 | 2022 | 516 | 0.450 |
Why?
|
| Ventricular Dysfunction, Right | 5 | 2019 | 218 | 0.440 |
Why?
|
| Purines | 6 | 2013 | 159 | 0.440 |
Why?
|
| Autoantigens | 1 | 2016 | 397 | 0.440 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2015 | 236 | 0.440 |
Why?
|
| Gene Expression | 5 | 2023 | 1422 | 0.440 |
Why?
|
| Arterial Pressure | 3 | 2019 | 99 | 0.440 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2013 | 19 | 0.430 |
Why?
|
| Ventricular Function, Right | 6 | 2021 | 252 | 0.430 |
Why?
|
| Culture Media, Conditioned | 1 | 2013 | 105 | 0.430 |
Why?
|
| Tracheostomy | 5 | 2021 | 100 | 0.430 |
Why?
|
| Respiratory Function Tests | 9 | 2020 | 524 | 0.420 |
Why?
|
| Nitric Oxide Synthase Type II | 5 | 2006 | 157 | 0.420 |
Why?
|
| Retrospective Studies | 32 | 2024 | 12544 | 0.420 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 1729 | 0.420 |
Why?
|
| T-Box Domain Proteins | 3 | 2023 | 92 | 0.420 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 89 | 0.420 |
Why?
|
| Reference Values | 9 | 2020 | 741 | 0.410 |
Why?
|
| Blood Vessels | 4 | 2016 | 180 | 0.410 |
Why?
|
| Umbilical Cord | 1 | 2013 | 80 | 0.410 |
Why?
|
| Forkhead Transcription Factors | 3 | 2023 | 171 | 0.410 |
Why?
|
| Potassium Channels | 3 | 2000 | 121 | 0.400 |
Why?
|
| Severity of Illness Index | 14 | 2019 | 2542 | 0.400 |
Why?
|
| MicroRNAs | 1 | 2018 | 601 | 0.400 |
Why?
|
| Age Factors | 11 | 2019 | 2891 | 0.400 |
Why?
|
| Amides | 3 | 2012 | 87 | 0.400 |
Why?
|
| Vasomotor System | 6 | 2002 | 39 | 0.400 |
Why?
|
| Estradiol | 3 | 2000 | 455 | 0.400 |
Why?
|
| Isoenzymes | 2 | 2011 | 285 | 0.400 |
Why?
|
| Follow-Up Studies | 15 | 2021 | 4427 | 0.390 |
Why?
|
| Mothers | 1 | 2017 | 651 | 0.390 |
Why?
|
| In Vitro Techniques | 6 | 2020 | 1034 | 0.370 |
Why?
|
| Organogenesis | 1 | 2011 | 54 | 0.370 |
Why?
|
| Cell Proliferation | 8 | 2015 | 2199 | 0.370 |
Why?
|
| History, 20th Century | 3 | 2017 | 267 | 0.370 |
Why?
|
| Registries | 4 | 2022 | 1760 | 0.360 |
Why?
|
| Alveolar Epithelial Cells | 3 | 2018 | 96 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2019 | 1856 | 0.350 |
Why?
|
| Cultural Diversity | 2 | 2020 | 55 | 0.350 |
Why?
|
| Atrial Natriuretic Factor | 3 | 1996 | 57 | 0.340 |
Why?
|
| Survival Rate | 11 | 2017 | 1644 | 0.340 |
Why?
|
| Culturally Competent Care | 2 | 2020 | 48 | 0.340 |
Why?
|
| Piperidines | 3 | 2016 | 162 | 0.340 |
Why?
|
| Adult | 23 | 2023 | 30608 | 0.340 |
Why?
|
| Health Status Indicators | 2 | 2020 | 154 | 0.340 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 386 | 0.340 |
Why?
|
| Oligopeptides | 3 | 2016 | 235 | 0.330 |
Why?
|
| Acute Lung Injury | 1 | 2013 | 300 | 0.330 |
Why?
|
| Regional Blood Flow | 6 | 2021 | 424 | 0.330 |
Why?
|
| Risk Assessment | 8 | 2019 | 2975 | 0.330 |
Why?
|
| Embryonic and Fetal Development | 6 | 2001 | 94 | 0.320 |
Why?
|
| Calcium Channel Blockers | 3 | 2007 | 115 | 0.320 |
Why?
|
| Intensive Care Units, Neonatal | 5 | 2024 | 176 | 0.310 |
Why?
|
| Endothelial Growth Factors | 3 | 2003 | 50 | 0.310 |
Why?
|
| Arginine | 7 | 1994 | 237 | 0.310 |
Why?
|
| Lymphokines | 3 | 2003 | 111 | 0.310 |
Why?
|
| Endothelium | 3 | 2015 | 112 | 0.310 |
Why?
|
| Biomarkers | 6 | 2020 | 3418 | 0.310 |
Why?
|
| Aorta | 7 | 2017 | 390 | 0.300 |
Why?
|
| Adolescent | 25 | 2021 | 17829 | 0.300 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2008 | 796 | 0.300 |
Why?
|
| Endothelin B Receptor Antagonists | 2 | 2005 | 11 | 0.300 |
Why?
|
| Phenyl Ethers | 1 | 2007 | 3 | 0.300 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2002 | 227 | 0.300 |
Why?
|
| Receptors, Growth Factor | 3 | 2002 | 49 | 0.300 |
Why?
|
| Iloprost | 1 | 2008 | 46 | 0.290 |
Why?
|
| Cohort Studies | 10 | 2024 | 4903 | 0.290 |
Why?
|
| Fluorocarbons | 2 | 1999 | 94 | 0.290 |
Why?
|
| Home Nursing | 3 | 2003 | 26 | 0.290 |
Why?
|
| Labor, Obstetric | 2 | 2001 | 52 | 0.280 |
Why?
|
| Disease Progression | 5 | 2018 | 2392 | 0.280 |
Why?
|
| RNA, Messenger | 11 | 2014 | 2559 | 0.280 |
Why?
|
| Asthma | 2 | 2021 | 2042 | 0.280 |
Why?
|
| Oxadiazoles | 3 | 2011 | 32 | 0.270 |
Why?
|
| Neonatal Screening | 7 | 1993 | 152 | 0.270 |
Why?
|
| Ductus Arteriosus, Patent | 3 | 2023 | 50 | 0.270 |
Why?
|
| Positive-Pressure Respiration | 4 | 2023 | 68 | 0.270 |
Why?
|
| Prognosis | 10 | 2019 | 3344 | 0.270 |
Why?
|
| Ligation | 5 | 2012 | 75 | 0.270 |
Why?
|
| Receptors, Cell Surface | 1 | 2008 | 354 | 0.270 |
Why?
|
| Receptor, Endothelin B | 6 | 2004 | 51 | 0.260 |
Why?
|
| Antigens, CD | 1 | 2008 | 443 | 0.260 |
Why?
|
| Glucocorticoids | 2 | 2000 | 534 | 0.260 |
Why?
|
| Logistic Models | 4 | 2020 | 1844 | 0.260 |
Why?
|
| Sulfonamides | 5 | 2016 | 445 | 0.260 |
Why?
|
| Research Personnel | 3 | 2020 | 151 | 0.250 |
Why?
|
| Recombinant Proteins | 5 | 2006 | 1233 | 0.250 |
Why?
|
| Bacteria | 1 | 2011 | 728 | 0.250 |
Why?
|
| Monitoring, Physiologic | 4 | 2019 | 248 | 0.250 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 686 | 0.250 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2005 | 40 | 0.250 |
Why?
|
| Ventricular Function, Left | 4 | 2017 | 468 | 0.250 |
Why?
|
| Amniotic Fluid | 3 | 2018 | 64 | 0.250 |
Why?
|
| Ventilator Weaning | 3 | 2016 | 33 | 0.250 |
Why?
|
| Apoptosis | 4 | 2013 | 2371 | 0.240 |
Why?
|
| Morbidity | 2 | 2023 | 277 | 0.240 |
Why?
|
| History, 21st Century | 2 | 2017 | 161 | 0.240 |
Why?
|
| Peptides, Cyclic | 5 | 2016 | 254 | 0.240 |
Why?
|
| Antioxidants | 3 | 2013 | 530 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2020 | 3053 | 0.240 |
Why?
|
| Hypertension | 4 | 2017 | 1059 | 0.240 |
Why?
|
| Exercise Tolerance | 1 | 2006 | 213 | 0.240 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2003 | 350 | 0.230 |
Why?
|
| Respiratory Therapy | 2 | 1994 | 19 | 0.230 |
Why?
|
| Fetal Development | 3 | 2022 | 247 | 0.230 |
Why?
|
| Asperger Syndrome | 1 | 2023 | 8 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 1400 | 0.230 |
Why?
|
| Prenatal Care | 3 | 2020 | 255 | 0.220 |
Why?
|
| Drug Administration Schedule | 4 | 2011 | 718 | 0.220 |
Why?
|
| Models, Animal | 2 | 2020 | 346 | 0.220 |
Why?
|
| Periodicals as Topic | 2 | 2017 | 181 | 0.220 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 90 | 0.220 |
Why?
|
| Physicians, Women | 2 | 2014 | 55 | 0.220 |
Why?
|
| Proteomics | 2 | 2020 | 844 | 0.210 |
Why?
|
| Oxidative Stress | 3 | 2018 | 1084 | 0.210 |
Why?
|
| Respiratory System Agents | 1 | 2023 | 22 | 0.210 |
Why?
|
| Young Adult | 10 | 2023 | 10478 | 0.210 |
Why?
|
| Placenta Growth Factor | 2 | 2022 | 22 | 0.210 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 131 | 0.210 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2003 | 82 | 0.210 |
Why?
|
| Fatal Outcome | 4 | 2018 | 285 | 0.210 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2016 | 396 | 0.210 |
Why?
|
| Ketanserin | 2 | 2013 | 12 | 0.210 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 2 | 2013 | 10 | 0.210 |
Why?
|
| Nitrites | 1 | 2002 | 74 | 0.210 |
Why?
|
| Oxygen Consumption | 3 | 2017 | 588 | 0.210 |
Why?
|
| Sudden Infant Death | 1 | 2022 | 24 | 0.210 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2022 | 11 | 0.210 |
Why?
|
| Sertraline | 2 | 2013 | 26 | 0.200 |
Why?
|
| Interdisciplinary Research | 1 | 2022 | 25 | 0.200 |
Why?
|
| Meconium Aspiration Syndrome | 3 | 2015 | 11 | 0.200 |
Why?
|
| Achievement | 1 | 2022 | 54 | 0.200 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 4 | 2006 | 22 | 0.200 |
Why?
|
| Angiography | 7 | 2002 | 176 | 0.200 |
Why?
|
| Blotting, Northern | 5 | 2000 | 193 | 0.200 |
Why?
|
| Analysis of Variance | 6 | 2012 | 1227 | 0.200 |
Why?
|
| Prevalence | 4 | 2021 | 2252 | 0.190 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 1126 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 2102 | 0.190 |
Why?
|
| Transcription Factors | 3 | 2023 | 1530 | 0.190 |
Why?
|
| Mice | 9 | 2015 | 14936 | 0.190 |
Why?
|
| Uterus | 1 | 2002 | 193 | 0.190 |
Why?
|
| Receptor, Endothelin A | 5 | 2000 | 59 | 0.190 |
Why?
|
| Pleural Effusion | 1 | 2021 | 47 | 0.190 |
Why?
|
| Therapies, Investigational | 1 | 2021 | 14 | 0.190 |
Why?
|
| Pneumonia | 2 | 2022 | 568 | 0.190 |
Why?
|
| Milrinone | 1 | 2021 | 24 | 0.190 |
Why?
|
| Amino Acids, Dicarboxylic | 1 | 2020 | 11 | 0.180 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2014 | 57 | 0.180 |
Why?
|
| Injections, Intralesional | 1 | 2020 | 32 | 0.180 |
Why?
|
| Microbiota | 2 | 2018 | 649 | 0.180 |
Why?
|
| Reperfusion Injury | 1 | 2023 | 254 | 0.180 |
Why?
|
| Soluble Guanylyl Cyclase | 2 | 2011 | 15 | 0.180 |
Why?
|
| Emergency Treatment | 1 | 2002 | 113 | 0.180 |
Why?
|
| Trust | 1 | 2021 | 105 | 0.180 |
Why?
|
| Causality | 2 | 2018 | 105 | 0.180 |
Why?
|
| Tissue Culture Techniques | 1 | 2020 | 66 | 0.180 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2000 | 48 | 0.180 |
Why?
|
| Betamethasone | 1 | 2000 | 19 | 0.180 |
Why?
|
| Pulse Wave Analysis | 2 | 2018 | 208 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 1215 | 0.180 |
Why?
|
| Gastroesophageal Reflux | 2 | 2022 | 234 | 0.180 |
Why?
|
| Interactive Ventilatory Support | 1 | 2020 | 2 | 0.180 |
Why?
|
| Longitudinal Studies | 5 | 2017 | 2382 | 0.180 |
Why?
|
| Current Procedural Terminology | 1 | 2020 | 11 | 0.170 |
Why?
|
| Lung Transplantation | 3 | 2019 | 246 | 0.170 |
Why?
|
| Mice, Knockout | 5 | 2016 | 2587 | 0.170 |
Why?
|
| Quinoxalines | 2 | 2011 | 60 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2013 | 496 | 0.170 |
Why?
|
| Random Allocation | 1 | 2020 | 335 | 0.170 |
Why?
|
| Colony-Forming Units Assay | 2 | 2009 | 89 | 0.170 |
Why?
|
| Heart Function Tests | 1 | 2019 | 58 | 0.170 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 136 | 0.170 |
Why?
|
| Clinical Trials as Topic | 3 | 2012 | 934 | 0.170 |
Why?
|
| Transportation of Patients | 2 | 2002 | 52 | 0.170 |
Why?
|
| Colorado | 5 | 2017 | 4091 | 0.170 |
Why?
|
| Morphogenesis | 2 | 2013 | 161 | 0.170 |
Why?
|
| Respiratory Tract Infections | 3 | 2021 | 321 | 0.160 |
Why?
|
| Blood Flow Velocity | 4 | 2019 | 387 | 0.160 |
Why?
|
| Natural Language Processing | 1 | 2020 | 71 | 0.160 |
Why?
|
| Potassium Channel Blockers | 1 | 1999 | 29 | 0.160 |
Why?
|
| Home Care Services | 2 | 2019 | 222 | 0.160 |
Why?
|
| Intubation, Intratracheal | 3 | 2017 | 215 | 0.160 |
Why?
|
| Maternal Exposure | 2 | 2012 | 138 | 0.160 |
Why?
|
| Scurvy | 1 | 2019 | 12 | 0.160 |
Why?
|
| Perfusion Imaging | 1 | 2019 | 51 | 0.160 |
Why?
|
| Endothelin A Receptor Antagonists | 2 | 2011 | 24 | 0.160 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 316 | 0.160 |
Why?
|
| Vitamin A | 3 | 2019 | 52 | 0.160 |
Why?
|
| Prostaglandins | 3 | 2007 | 78 | 0.160 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 2770 | 0.160 |
Why?
|
| Incidence | 6 | 2015 | 2316 | 0.160 |
Why?
|
| Coculture Techniques | 2 | 2016 | 201 | 0.160 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 1440 | 0.160 |
Why?
|
| Constriction | 3 | 2008 | 45 | 0.160 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2018 | 25 | 0.150 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 22 | 0.150 |
Why?
|
| Phosphorylation | 3 | 2015 | 1572 | 0.150 |
Why?
|
| Placental Insufficiency | 2 | 2014 | 102 | 0.150 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2017 | 486 | 0.150 |
Why?
|
| Serum Albumin | 3 | 1992 | 134 | 0.150 |
Why?
|
| Dexamethasone | 1 | 2000 | 317 | 0.150 |
Why?
|
| Myocardial Contraction | 2 | 2019 | 312 | 0.150 |
Why?
|
| Air | 2 | 2009 | 33 | 0.150 |
Why?
|
| Elastin | 2 | 2015 | 78 | 0.150 |
Why?
|
| Thermodilution | 1 | 2017 | 12 | 0.150 |
Why?
|
| Survival Analysis | 5 | 2019 | 1220 | 0.150 |
Why?
|
| Gene Deletion | 1 | 2019 | 356 | 0.150 |
Why?
|
| Stroke Volume | 2 | 2018 | 510 | 0.150 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 83 | 0.150 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2007 | 215 | 0.150 |
Why?
|
| Education, Medical | 1 | 2020 | 222 | 0.150 |
Why?
|
| Refractometry | 1 | 2017 | 27 | 0.150 |
Why?
|
| Respiratory System | 1 | 2018 | 138 | 0.140 |
Why?
|
| Flow Cytometry | 2 | 2012 | 1087 | 0.140 |
Why?
|
| Membrane Proteins | 1 | 2023 | 1022 | 0.140 |
Why?
|
| Ventilators, Mechanical | 3 | 2021 | 52 | 0.140 |
Why?
|
| Optical Imaging | 1 | 2017 | 54 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 243 | 0.140 |
Why?
|
| Immunomodulation | 1 | 2018 | 84 | 0.140 |
Why?
|
| Continuity of Patient Care | 2 | 2016 | 254 | 0.140 |
Why?
|
| Dysbiosis | 1 | 2018 | 146 | 0.140 |
Why?
|
| Retinal Vessels | 1 | 2017 | 50 | 0.140 |
Why?
|
| Dietary Supplements | 3 | 2019 | 458 | 0.140 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2019 | 221 | 0.140 |
Why?
|
| Methemoglobin | 2 | 1993 | 19 | 0.140 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 414 | 0.140 |
Why?
|
| Collagen Type XVIII | 1 | 2016 | 4 | 0.140 |
Why?
|
| Inflammation | 3 | 2021 | 2485 | 0.140 |
Why?
|
| Injections, Intraperitoneal | 1 | 2016 | 100 | 0.140 |
Why?
|
| Capillary Permeability | 1 | 1997 | 135 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2021 | 824 | 0.140 |
Why?
|
| Leukocyte Count | 2 | 2013 | 292 | 0.140 |
Why?
|
| Family | 1 | 2020 | 590 | 0.140 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 638 | 0.140 |
Why?
|
| Stress, Mechanical | 4 | 2019 | 447 | 0.140 |
Why?
|
| Social Class | 1 | 2018 | 204 | 0.140 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2019 | 36 | 0.130 |
Why?
|
| Scimitar Syndrome | 1 | 2016 | 6 | 0.130 |
Why?
|
| Endothelin-3 | 1 | 1996 | 3 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 2015 | 2133 | 0.130 |
Why?
|
| Neutrophils | 3 | 2004 | 1164 | 0.130 |
Why?
|
| Altitude Sickness | 1 | 2018 | 172 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 525 | 0.130 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 316 | 0.130 |
Why?
|
| Survivors | 1 | 2019 | 411 | 0.130 |
Why?
|
| Hemoptysis | 1 | 2016 | 35 | 0.130 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1998 | 159 | 0.130 |
Why?
|
| Veins | 1 | 2016 | 56 | 0.130 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2015 | 14 | 0.130 |
Why?
|
| Cell Adhesion | 2 | 2016 | 430 | 0.130 |
Why?
|
| Case-Control Studies | 5 | 2019 | 3008 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 4 | 2016 | 4719 | 0.130 |
Why?
|
| Aging | 4 | 2007 | 1621 | 0.130 |
Why?
|
| Calcifediol | 1 | 2015 | 29 | 0.130 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 398 | 0.130 |
Why?
|
| Interleukin-6 | 1 | 1999 | 676 | 0.130 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2015 | 9 | 0.130 |
Why?
|
| Microvessels | 1 | 2016 | 68 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 1477 | 0.120 |
Why?
|
| Genetic Counseling | 1 | 2015 | 65 | 0.120 |
Why?
|
| Probability | 2 | 2008 | 291 | 0.120 |
Why?
|
| Respiration | 5 | 2018 | 180 | 0.120 |
Why?
|
| Treatment Failure | 4 | 2007 | 332 | 0.120 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2015 | 49 | 0.120 |
Why?
|
| Indiana | 1 | 2015 | 27 | 0.120 |
Why?
|
| Retina | 1 | 2017 | 263 | 0.120 |
Why?
|
| Interleukin-1 | 1 | 1999 | 966 | 0.120 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1994 | 18 | 0.120 |
Why?
|
| Abnormalities, Multiple | 1 | 2016 | 177 | 0.120 |
Why?
|
| Cell Division | 2 | 2007 | 759 | 0.120 |
Why?
|
| Patient Discharge | 2 | 2022 | 769 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 2016 | 210 | 0.120 |
Why?
|
| Nitroprusside | 2 | 2011 | 64 | 0.120 |
Why?
|
| Transcriptome | 1 | 2020 | 728 | 0.120 |
Why?
|
| Arteriovenous Fistula | 1 | 2014 | 29 | 0.120 |
Why?
|
| Fibroblast Growth Factors | 1 | 2015 | 162 | 0.120 |
Why?
|
| Contrast Media | 1 | 2017 | 353 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 82 | 0.120 |
Why?
|
| Extracellular Matrix | 2 | 2014 | 436 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 929 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2019 | 499 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 1134 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 744 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1081 | 0.110 |
Why?
|
| Sulfur | 1 | 2014 | 46 | 0.110 |
Why?
|
| Developmental Disabilities | 2 | 2014 | 239 | 0.110 |
Why?
|
| Taurine | 1 | 2014 | 41 | 0.110 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 61 | 0.110 |
Why?
|
| Vascular Remodeling | 1 | 2015 | 153 | 0.110 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2014 | 59 | 0.110 |
Why?
|
| Vasopressins | 1 | 2014 | 56 | 0.110 |
Why?
|
| Embryo, Mammalian | 1 | 2014 | 214 | 0.110 |
Why?
|
| Schools, Medical | 1 | 2015 | 122 | 0.110 |
Why?
|
| Cardiac Output | 3 | 2017 | 143 | 0.110 |
Why?
|
| Glycopeptides | 1 | 1994 | 43 | 0.110 |
Why?
|
| Immunologic Techniques | 3 | 1999 | 39 | 0.110 |
Why?
|
| Vasoconstrictor Agents | 1 | 2014 | 112 | 0.110 |
Why?
|
| Collagen | 2 | 2014 | 416 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2018 | 1699 | 0.110 |
Why?
|
| Homocystinuria | 1 | 2014 | 62 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1325 | 0.110 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2004 | 64 | 0.110 |
Why?
|
| Cerebrovascular Circulation | 1 | 1995 | 220 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2016 | 812 | 0.110 |
Why?
|
| Sheep, Domestic | 1 | 2013 | 33 | 0.110 |
Why?
|
| Acute Disease | 5 | 2005 | 915 | 0.110 |
Why?
|
| Pain | 1 | 2019 | 710 | 0.110 |
Why?
|
| Cysteine | 1 | 2014 | 171 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2020 | 802 | 0.110 |
Why?
|
| Decision Making | 1 | 2019 | 781 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 290 | 0.110 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2013 | 52 | 0.110 |
Why?
|
| I-kappa B Kinase | 1 | 2013 | 50 | 0.110 |
Why?
|
| Hypotension | 1 | 2014 | 113 | 0.110 |
Why?
|
| Quality Improvement | 2 | 2017 | 954 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 195 | 0.100 |
Why?
|
| Molecular Biology | 1 | 2013 | 56 | 0.100 |
Why?
|
| I-kappa B Proteins | 1 | 2013 | 78 | 0.100 |
Why?
|
| Staining and Labeling | 4 | 1997 | 134 | 0.100 |
Why?
|
| Diastole | 2 | 2015 | 131 | 0.100 |
Why?
|
| Career Mobility | 1 | 2013 | 63 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 109 | 0.100 |
Why?
|
| Streptococcus agalactiae | 1 | 1993 | 81 | 0.100 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2012 | 63 | 0.100 |
Why?
|
| Global Health | 2 | 2019 | 288 | 0.100 |
Why?
|
| Length of Stay | 2 | 2016 | 949 | 0.100 |
Why?
|
| Cadaver | 1 | 2013 | 303 | 0.100 |
Why?
|
| Research Support as Topic | 1 | 2013 | 108 | 0.100 |
Why?
|
| Pancreas | 1 | 2014 | 277 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 928 | 0.100 |
Why?
|
| Carbon Dioxide | 3 | 2000 | 218 | 0.100 |
Why?
|
| Airway Obstruction | 2 | 1984 | 168 | 0.100 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 172 | 0.100 |
Why?
|
| Hydrogels | 1 | 2018 | 573 | 0.100 |
Why?
|
| Hysterotomy | 1 | 2011 | 10 | 0.100 |
Why?
|
| Cell Aggregation | 1 | 2011 | 24 | 0.100 |
Why?
|
| Eicosanoids | 1 | 1992 | 54 | 0.100 |
Why?
|
| Streptococcal Infections | 1 | 1993 | 127 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 4635 | 0.100 |
Why?
|
| Receptors, Serotonin | 1 | 2011 | 32 | 0.100 |
Why?
|
| DNA Primers | 1 | 2012 | 514 | 0.100 |
Why?
|
| Suction | 1 | 2011 | 31 | 0.100 |
Why?
|
| Bacterial Load | 1 | 2011 | 58 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2012 | 184 | 0.100 |
Why?
|
| Guanidines | 3 | 2001 | 33 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2015 | 633 | 0.090 |
Why?
|
| Receptor, Insulin | 1 | 2011 | 93 | 0.090 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 1317 | 0.090 |
Why?
|
| Fluoxetine | 1 | 2011 | 46 | 0.090 |
Why?
|
| Antibodies | 1 | 1993 | 372 | 0.090 |
Why?
|
| Protein Binding | 1 | 2016 | 1897 | 0.090 |
Why?
|
| Primary Cell Culture | 1 | 2011 | 149 | 0.090 |
Why?
|
| Macrophages | 1 | 2018 | 1266 | 0.090 |
Why?
|
| RNA, Ribosomal | 1 | 2011 | 157 | 0.090 |
Why?
|
| RNA Interference | 1 | 2012 | 437 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 313 | 0.090 |
Why?
|
| Communication | 1 | 2016 | 749 | 0.090 |
Why?
|
| Metagenome | 1 | 2011 | 122 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 1355 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 220 | 0.090 |
Why?
|
| RNA, Bacterial | 1 | 2011 | 174 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 797 | 0.090 |
Why?
|
| Adenosine Triphosphate | 1 | 1992 | 431 | 0.090 |
Why?
|
| Hospital Mortality | 1 | 2014 | 776 | 0.090 |
Why?
|
| Patient Readmission | 2 | 2013 | 608 | 0.090 |
Why?
|
| Forecasting | 1 | 2012 | 333 | 0.090 |
Why?
|
| Rats, Inbred Strains | 2 | 2001 | 366 | 0.090 |
Why?
|
| Gelatin | 2 | 2000 | 36 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1523 | 0.090 |
Why?
|
| Hydrogen Peroxide | 1 | 2011 | 287 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 476 | 0.090 |
Why?
|
| Delivery, Obstetric | 1 | 1990 | 119 | 0.090 |
Why?
|
| Pilot Projects | 4 | 2020 | 1372 | 0.080 |
Why?
|
| Cell Shape | 1 | 2009 | 54 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2013 | 619 | 0.080 |
Why?
|
| Death, Sudden | 1 | 1989 | 27 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 400 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2013 | 637 | 0.080 |
Why?
|
| Cell Count | 1 | 2009 | 305 | 0.080 |
Why?
|
| Respirovirus Infections | 1 | 1988 | 21 | 0.080 |
Why?
|
| Cesarean Section | 3 | 2000 | 169 | 0.080 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2010 | 98 | 0.080 |
Why?
|
| Heart Failure | 1 | 2021 | 1952 | 0.080 |
Why?
|
| Myosin-Light-Chain Phosphatase | 1 | 2008 | 3 | 0.080 |
Why?
|
| Research | 1 | 2012 | 395 | 0.080 |
Why?
|
| Endoglin | 1 | 2008 | 20 | 0.080 |
Why?
|
| Pressure | 2 | 2002 | 218 | 0.080 |
Why?
|
| Regression Analysis | 3 | 2020 | 947 | 0.080 |
Why?
|
| Islets of Langerhans | 1 | 2014 | 728 | 0.080 |
Why?
|
| Hyponatremia | 1 | 1988 | 37 | 0.080 |
Why?
|
| Dipeptides | 1 | 2008 | 48 | 0.080 |
Why?
|
| Sodium Chloride | 1 | 1988 | 136 | 0.070 |
Why?
|
| Purinones | 2 | 1998 | 4 | 0.070 |
Why?
|
| Heart Rate, Fetal | 2 | 1999 | 20 | 0.070 |
Why?
|
| Cell Movement | 1 | 2011 | 867 | 0.070 |
Why?
|
| Time | 2 | 2005 | 70 | 0.070 |
Why?
|
| Staphylococcus | 2 | 2017 | 69 | 0.070 |
Why?
|
| Tolazoline | 1 | 1986 | 3 | 0.070 |
Why?
|
| Diseases in Twins | 1 | 2008 | 174 | 0.070 |
Why?
|
| Norepinephrine | 1 | 1987 | 207 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 123 | 0.070 |
Why?
|
| Leukomalacia, Periventricular | 1 | 2006 | 7 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2005 | 286 | 0.070 |
Why?
|
| Mice, Transgenic | 3 | 2017 | 1953 | 0.070 |
Why?
|
| Diuretics | 2 | 2019 | 66 | 0.070 |
Why?
|
| Protein-Energy Malnutrition | 1 | 1986 | 6 | 0.070 |
Why?
|
| Muscle, Smooth | 2 | 2000 | 147 | 0.070 |
Why?
|
| Liver | 1 | 2014 | 1634 | 0.070 |
Why?
|
| Partial Pressure | 2 | 2002 | 30 | 0.070 |
Why?
|
| Drug Synergism | 2 | 1998 | 316 | 0.070 |
Why?
|
| S-Nitroso-N-Acetylpenicillamine | 1 | 2006 | 4 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 1998 | 441 | 0.070 |
Why?
|
| Neoplasms | 1 | 2019 | 2106 | 0.070 |
Why?
|
| Isoxazoles | 1 | 2006 | 52 | 0.070 |
Why?
|
| Nitric Oxide Donors | 1 | 2006 | 15 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2008 | 679 | 0.070 |
Why?
|
| Intracranial Hemorrhages | 1 | 2006 | 76 | 0.060 |
Why?
|
| Thiophenes | 1 | 2006 | 108 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 1989 | 483 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 249 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 225 | 0.060 |
Why?
|
| Hypertrophy | 1 | 2005 | 111 | 0.060 |
Why?
|
| Heart | 2 | 2000 | 609 | 0.060 |
Why?
|
| Myocardium | 2 | 2000 | 911 | 0.060 |
Why?
|
| Cardiomegaly | 3 | 1997 | 159 | 0.060 |
Why?
|
| Calcium | 3 | 1996 | 1104 | 0.060 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2004 | 44 | 0.060 |
Why?
|
| Postoperative Period | 2 | 1998 | 289 | 0.060 |
Why?
|
| Steroids | 2 | 2016 | 146 | 0.060 |
Why?
|
| Blood Gas Analysis | 3 | 2000 | 73 | 0.060 |
Why?
|
| Methacholine Chloride | 1 | 2024 | 47 | 0.060 |
Why?
|
| Heart Atria | 1 | 2004 | 110 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 399 | 0.060 |
Why?
|
| X-Ray Microtomography | 1 | 2024 | 74 | 0.060 |
Why?
|
| Injections, Intra-Arterial | 2 | 2000 | 25 | 0.060 |
Why?
|
| Pulse Therapy, Drug | 1 | 2003 | 6 | 0.060 |
Why?
|
| Parturition | 1 | 2004 | 54 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 1801 | 0.060 |
Why?
|
| Administration, Intranasal | 1 | 2003 | 75 | 0.060 |
Why?
|
| In Situ Hybridization | 2 | 2001 | 293 | 0.060 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2004 | 74 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1700 | 0.050 |
Why?
|
| Gastrostomy | 2 | 2021 | 89 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 25 | 0.050 |
Why?
|
| Infant Death | 1 | 2022 | 4 | 0.050 |
Why?
|
| Hematocrit | 2 | 2000 | 85 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 40 | 0.050 |
Why?
|
| Surface-Active Agents | 1 | 2023 | 79 | 0.050 |
Why?
|
| Arteriovenous Malformations | 1 | 2022 | 24 | 0.050 |
Why?
|
| Foreign Bodies | 1 | 1984 | 99 | 0.050 |
Why?
|
| Mice, Mutant Strains | 1 | 2003 | 272 | 0.050 |
Why?
|
| Ambulatory Care | 2 | 2022 | 479 | 0.050 |
Why?
|
| Quality of Life | 2 | 2010 | 2359 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2022 | 79 | 0.050 |
Why?
|
| Mosaicism | 1 | 2022 | 61 | 0.050 |
Why?
|
| Injections | 2 | 1994 | 159 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2022 | 168 | 0.050 |
Why?
|
| Nifedipine | 1 | 2002 | 29 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2023 | 331 | 0.050 |
Why?
|
| Heterozygote | 2 | 2019 | 251 | 0.050 |
Why?
|
| Insulin | 1 | 2011 | 2079 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2002 | 138 | 0.050 |
Why?
|
| Fetal Hypoxia | 1 | 2022 | 47 | 0.050 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2001 | 12 | 0.050 |
Why?
|
| Ciliary Motility Disorders | 1 | 2021 | 21 | 0.050 |
Why?
|
| Placentation | 1 | 2021 | 40 | 0.050 |
Why?
|
| Radioligand Assay | 1 | 2001 | 43 | 0.050 |
Why?
|
| Amidines | 1 | 2001 | 16 | 0.050 |
Why?
|
| Benzylamines | 1 | 2001 | 39 | 0.050 |
Why?
|
| Mutation | 2 | 2023 | 3354 | 0.050 |
Why?
|
| Delayed Rectifier Potassium Channels | 1 | 2000 | 9 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2002 | 146 | 0.050 |
Why?
|
| Evidence-Based Medicine | 4 | 2007 | 675 | 0.050 |
Why?
|
| Ligands | 1 | 2003 | 565 | 0.050 |
Why?
|
| Perfusion | 2 | 1994 | 150 | 0.050 |
Why?
|
| Barium Sulfate | 1 | 2000 | 15 | 0.050 |
Why?
|
| Cyclohexanes | 1 | 2000 | 22 | 0.050 |
Why?
|
| Exercise Test | 2 | 2019 | 545 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2000 | 77 | 0.040 |
Why?
|
| Plethysmography | 1 | 2001 | 104 | 0.040 |
Why?
|
| Vaping | 1 | 2021 | 45 | 0.040 |
Why?
|
| Thalidomide | 1 | 2000 | 28 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2001 | 215 | 0.040 |
Why?
|
| Sesquiterpenes | 1 | 2000 | 51 | 0.040 |
Why?
|
| Heart Septum | 1 | 2000 | 26 | 0.040 |
Why?
|
| Barium | 1 | 2000 | 25 | 0.040 |
Why?
|
| Pharmacovigilance | 1 | 2020 | 14 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 534 | 0.040 |
Why?
|
| Pediatricians | 1 | 2021 | 122 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2000 | 84 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2000 | 118 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2000 | 325 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 353 | 0.040 |
Why?
|
| Carbon Monoxide | 1 | 2000 | 65 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2000 | 25 | 0.040 |
Why?
|
| Physician's Role | 1 | 2021 | 198 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 737 | 0.040 |
Why?
|
| Physical Stimulation | 1 | 2000 | 78 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2002 | 144 | 0.040 |
Why?
|
| Fever | 1 | 2001 | 279 | 0.040 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 48 | 0.040 |
Why?
|
| Algorithms | 3 | 2007 | 1474 | 0.040 |
Why?
|
| Indazoles | 1 | 2000 | 58 | 0.040 |
Why?
|
| Ventricular Pressure | 2 | 2015 | 37 | 0.040 |
Why?
|
| Systole | 1 | 2000 | 171 | 0.040 |
Why?
|
| Hot Temperature | 1 | 2001 | 304 | 0.040 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2010 | 46 | 0.040 |
Why?
|
| Hydrocarbons, Brominated | 1 | 1999 | 5 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2002 | 378 | 0.040 |
Why?
|
| Charybdotoxin | 1 | 1999 | 6 | 0.040 |
Why?
|
| Tetraethylammonium | 1 | 1999 | 15 | 0.040 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 1999 | 57 | 0.040 |
Why?
|
| Respiratory Mechanics | 1 | 1999 | 56 | 0.040 |
Why?
|
| Gingiva | 1 | 2019 | 22 | 0.040 |
Why?
|
| 4-Aminopyridine | 1 | 1999 | 21 | 0.040 |
Why?
|
| Air Pollution | 1 | 2021 | 170 | 0.040 |
Why?
|
| Mechanical Phenomena | 1 | 2019 | 80 | 0.040 |
Why?
|
| Societies | 1 | 2019 | 37 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 1999 | 96 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1999 | 108 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 145 | 0.040 |
Why?
|
| Atrial Function, Right | 1 | 1998 | 12 | 0.040 |
Why?
|
| Caffeine | 1 | 2019 | 57 | 0.040 |
Why?
|
| Blood Circulation | 1 | 1998 | 34 | 0.040 |
Why?
|
| Cholecalciferol | 1 | 2019 | 47 | 0.040 |
Why?
|
| Drug Therapy, Combination | 3 | 2007 | 954 | 0.040 |
Why?
|
| Chest Pain | 1 | 2019 | 81 | 0.040 |
Why?
|
| Progestins | 1 | 2019 | 75 | 0.040 |
Why?
|
| Nutritional Status | 2 | 1992 | 286 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 159 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 387 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2019 | 111 | 0.040 |
Why?
|
| North America | 1 | 2019 | 257 | 0.040 |
Why?
|
| Tissue Distribution | 2 | 1999 | 285 | 0.040 |
Why?
|
| Asphyxia Neonatorum | 1 | 1998 | 15 | 0.040 |
Why?
|
| Nose | 1 | 1998 | 55 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 2019 | 110 | 0.040 |
Why?
|
| Isothiuronium | 1 | 1998 | 3 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 611 | 0.040 |
Why?
|
| Thiazines | 1 | 1998 | 9 | 0.040 |
Why?
|
| Long-Term Care | 1 | 1998 | 77 | 0.040 |
Why?
|
| Masks | 1 | 1998 | 46 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 244 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 581 | 0.040 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2018 | 70 | 0.040 |
Why?
|
| Catheterization | 1 | 1998 | 160 | 0.040 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2017 | 34 | 0.040 |
Why?
|
| Progesterone | 1 | 2019 | 232 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 340 | 0.040 |
Why?
|
| Medical Records | 1 | 1998 | 154 | 0.040 |
Why?
|
| Phentolamine | 2 | 1987 | 17 | 0.040 |
Why?
|
| Biological Products | 1 | 2000 | 169 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 336 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2019 | 246 | 0.040 |
Why?
|
| Iron | 1 | 2019 | 233 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 1997 | 84 | 0.040 |
Why?
|
| Leg | 1 | 2019 | 225 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 1998 | 123 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2017 | 57 | 0.040 |
Why?
|
| Shear Strength | 1 | 2017 | 65 | 0.040 |
Why?
|
| Infusions, Intra-Arterial | 2 | 1991 | 46 | 0.040 |
Why?
|
| Travel | 1 | 2018 | 121 | 0.040 |
Why?
|
| Respiratory Mucosa | 1 | 2019 | 251 | 0.030 |
Why?
|
| Methylene Blue | 1 | 1996 | 22 | 0.030 |
Why?
|
| Fibrosis | 1 | 2019 | 454 | 0.030 |
Why?
|
| Fellowships and Scholarships | 2 | 2010 | 227 | 0.030 |
Why?
|
| Indomethacin | 1 | 1996 | 74 | 0.030 |
Why?
|
| Education | 1 | 2017 | 95 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 1133 | 0.030 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1996 | 72 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 1988 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 1997 | 73 | 0.030 |
Why?
|
| Patient Selection | 1 | 2000 | 642 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1997 | 165 | 0.030 |
Why?
|
| Expectorants | 1 | 2016 | 24 | 0.030 |
Why?
|
| Growth | 2 | 1997 | 56 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 305 | 0.030 |
Why?
|
| Adenosine | 1 | 1998 | 202 | 0.030 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2016 | 44 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 297 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2004 | 590 | 0.030 |
Why?
|
| Autopsy | 1 | 2016 | 85 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1080 | 0.030 |
Why?
|
| Middle Aged | 4 | 2021 | 26806 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 2791 | 0.030 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 1995 | 7 | 0.030 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1995 | 23 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1045 | 0.030 |
Why?
|
| Arterioles | 1 | 1995 | 39 | 0.030 |
Why?
|
| Theophylline | 1 | 1995 | 60 | 0.030 |
Why?
|
| Rabbits | 1 | 1996 | 748 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1999 | 1663 | 0.030 |
Why?
|
| Neurotransmitter Agents | 1 | 1995 | 77 | 0.030 |
Why?
|
| Phenylephrine | 1 | 1995 | 74 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 817 | 0.030 |
Why?
|
| Catalase | 1 | 2015 | 117 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2019 | 618 | 0.030 |
Why?
|
| Cysteine Dioxygenase | 1 | 2014 | 3 | 0.030 |
Why?
|
| Carboxy-Lyases | 1 | 2014 | 8 | 0.030 |
Why?
|
| Sepharose | 1 | 1994 | 31 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2019 | 876 | 0.030 |
Why?
|
| Frozen Sections | 1 | 1994 | 24 | 0.030 |
Why?
|
| Viper Venoms | 1 | 1994 | 9 | 0.030 |
Why?
|
| Muscle Tonus | 1 | 1994 | 18 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 692 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2017 | 672 | 0.030 |
Why?
|
| Costs and Cost Analysis | 2 | 2009 | 195 | 0.030 |
Why?
|
| Netherlands | 1 | 2013 | 64 | 0.030 |
Why?
|
| Guanosine Monophosphate | 1 | 2013 | 7 | 0.030 |
Why?
|
| Intermittent Positive-Pressure Ventilation | 1 | 1993 | 9 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1458 | 0.030 |
Why?
|
| Methionine | 1 | 2014 | 144 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1125 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 1993 | 77 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 164 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 1994 | 250 | 0.030 |
Why?
|
| Meclofenamic Acid | 2 | 1991 | 4 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 834 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 430 | 0.030 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2013 | 52 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 258 | 0.030 |
Why?
|
| Cromakalim | 1 | 1992 | 1 | 0.030 |
Why?
|
| Benzopyrans | 1 | 1992 | 25 | 0.030 |
Why?
|
| Cytosol | 1 | 1993 | 208 | 0.030 |
Why?
|
| Glyburide | 1 | 1992 | 35 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 543 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 1995 | 296 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 536 | 0.030 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 1992 | 17 | 0.030 |
Why?
|
| Aged | 2 | 2021 | 19122 | 0.020 |
Why?
|
| Verapamil | 2 | 1994 | 32 | 0.020 |
Why?
|
| Trypsinogen | 1 | 1991 | 9 | 0.020 |
Why?
|
| Venae Cavae | 1 | 1991 | 9 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 723 | 0.020 |
Why?
|
| Exercise | 1 | 2022 | 1643 | 0.020 |
Why?
|
| Haemophilus influenzae | 1 | 1991 | 48 | 0.020 |
Why?
|
| Pharynx | 1 | 1991 | 50 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1991 | 88 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 1991 | 138 | 0.020 |
Why?
|
| Critical Care | 1 | 1995 | 474 | 0.020 |
Why?
|
| omega-N-Methylarginine | 1 | 1990 | 25 | 0.020 |
Why?
|
| Prostaglandin D2 | 1 | 1991 | 21 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 927 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 1991 | 143 | 0.020 |
Why?
|
| Vitamin E Deficiency | 1 | 1991 | 42 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 1991 | 81 | 0.020 |
Why?
|
| Vitamin A Deficiency | 1 | 1991 | 27 | 0.020 |
Why?
|
| Platelet Activating Factor | 1 | 1991 | 87 | 0.020 |
Why?
|
| Muscle Development | 1 | 1991 | 98 | 0.020 |
Why?
|
| Pancreatin | 2 | 1991 | 5 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 6364 | 0.020 |
Why?
|
| Intensive Care, Neonatal | 1 | 2010 | 39 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 1991 | 185 | 0.020 |
Why?
|
| Accreditation | 1 | 2010 | 78 | 0.020 |
Why?
|
| Tissue Banks | 1 | 2009 | 18 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 2009 | 47 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2009 | 114 | 0.020 |
Why?
|
| Brain | 2 | 2017 | 2372 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1991 | 299 | 0.020 |
Why?
|
| Obesity | 1 | 2021 | 2514 | 0.020 |
Why?
|
| Pulmonary Heart Disease | 1 | 1988 | 6 | 0.020 |
Why?
|
| Microcirculation | 1 | 2009 | 135 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2010 | 147 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 106 | 0.020 |
Why?
|
| Sheep Diseases | 1 | 1988 | 7 | 0.020 |
Why?
|
| Chest Wall Oscillation | 1 | 2007 | 4 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 1991 | 385 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1987 | 30 | 0.020 |
Why?
|
| Kinetics | 1 | 1991 | 1555 | 0.020 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2007 | 26 | 0.020 |
Why?
|
| Cimetidine | 1 | 1986 | 15 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2007 | 52 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 546 | 0.020 |
Why?
|
| Diphenhydramine | 1 | 1986 | 30 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2326 | 0.020 |
Why?
|
| Epinephrine | 1 | 1987 | 167 | 0.020 |
Why?
|
| Hypoproteinemia | 1 | 1986 | 4 | 0.020 |
Why?
|
| Pancreatic Extracts | 1 | 1985 | 2 | 0.020 |
Why?
|
| Tablets, Enteric-Coated | 1 | 1985 | 4 | 0.020 |
Why?
|
| Pancrelipase | 1 | 1985 | 6 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 374 | 0.020 |
Why?
|
| Lipase | 1 | 1985 | 57 | 0.020 |
Why?
|
| Edema | 1 | 1986 | 119 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 819 | 0.020 |
Why?
|
| Anemia | 1 | 1986 | 144 | 0.020 |
Why?
|
| Failure to Thrive | 1 | 1984 | 32 | 0.010 |
Why?
|
| Hydrochlorothiazide | 1 | 1984 | 8 | 0.010 |
Why?
|
| Propranolol | 1 | 1984 | 53 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1986 | 219 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 297 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 464 | 0.010 |
Why?
|
| Heart Rate | 1 | 1986 | 705 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 238 | 0.010 |
Why?
|
| Emergencies | 1 | 1984 | 146 | 0.010 |
Why?
|
| Child Health Services | 1 | 1984 | 177 | 0.010 |
Why?
|
| Ebstein Anomaly | 1 | 1981 | 6 | 0.010 |
Why?
|
| Prostaglandins E | 1 | 1981 | 46 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2004 | 562 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2000 | 49 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 47 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 119 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 69 | 0.010 |
Why?
|
| Calibration | 1 | 2001 | 125 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2000 | 78 | 0.010 |
Why?
|
| Protoporphyrins | 1 | 2000 | 17 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 107 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2000 | 99 | 0.010 |
Why?
|
| Vitamin E | 2 | 1991 | 110 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2000 | 238 | 0.010 |
Why?
|
| CREST Syndrome | 1 | 1999 | 6 | 0.010 |
Why?
|
| Caspases | 1 | 2000 | 245 | 0.010 |
Why?
|
| Lung Volume Measurements | 1 | 1999 | 45 | 0.010 |
Why?
|
| Monocrotaline | 1 | 1999 | 33 | 0.010 |
Why?
|
| Rats, Mutant Strains | 1 | 1999 | 25 | 0.010 |
Why?
|
| Sex Factors | 1 | 1984 | 1721 | 0.010 |
Why?
|
| Mass Screening | 1 | 1985 | 1011 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1999 | 209 | 0.010 |
Why?
|
| Homozygote | 1 | 1999 | 188 | 0.010 |
Why?
|
| Child Development | 2 | 1997 | 387 | 0.010 |
Why?
|
| Frontal Bone | 1 | 1997 | 13 | 0.010 |
Why?
|
| Occipital Bone | 1 | 1997 | 18 | 0.010 |
Why?
|
| Cephalometry | 1 | 1997 | 28 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1999 | 228 | 0.010 |
Why?
|
| Body Height | 1 | 1997 | 180 | 0.010 |
Why?
|
| Enteral Nutrition | 1 | 1997 | 157 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2000 | 958 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 1997 | 280 | 0.010 |
Why?
|
| Fixatives | 1 | 1994 | 16 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1994 | 46 | 0.010 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 1994 | 11 | 0.010 |
Why?
|
| Ryanodine | 1 | 1994 | 13 | 0.010 |
Why?
|
| Manganese | 1 | 1994 | 55 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1994 | 201 | 0.010 |
Why?
|
| Fluorescence | 1 | 1994 | 148 | 0.010 |
Why?
|
| Angiotensin II | 1 | 1993 | 90 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1992 | 51 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 1993 | 180 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1991 | 50 | 0.010 |
Why?
|
| Sweat | 1 | 1991 | 38 | 0.010 |
Why?
|
| Anthropometry | 1 | 1992 | 180 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1991 | 109 | 0.010 |
Why?
|
| Phospholipid Ethers | 1 | 1991 | 7 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 1992 | 123 | 0.010 |
Why?
|
| Polymers | 1 | 1994 | 447 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1991 | 232 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1992 | 287 | 0.010 |
Why?
|
| Hydroxycholecalciferols | 1 | 1989 | 3 | 0.010 |
Why?
|
| Infant Nutrition Disorders | 1 | 1989 | 11 | 0.010 |
Why?
|
| Vitamin K | 1 | 1989 | 42 | 0.010 |
Why?
|
| Energy Intake | 1 | 1992 | 420 | 0.010 |
Why?
|
| Solubility | 1 | 1989 | 224 | 0.010 |
Why?
|
| Breast Feeding | 1 | 1992 | 370 | 0.000 |
Why?
|
| Genotype | 1 | 1993 | 1775 | 0.000 |
Why?
|
| Lipids | 1 | 1989 | 582 | 0.000 |
Why?
|
| HIV Infections | 1 | 1999 | 2470 | 0.000 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1984 | 79 | 0.000 |
Why?
|
| Digoxin | 1 | 1981 | 26 | 0.000 |
Why?
|
| Furosemide | 1 | 1981 | 32 | 0.000 |
Why?
|